JRC Publications Repository

JRC Publications Repository >

Browsing by Author BRUCHERTSEIFER Frank

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:   
Sort by: In order: Results/Page Authors/Record:
Showing results 2 to 21 of 86
Publication YearTitleAuthor(s), Editor(s), Other Contributor(s)Publication Type
2013213-Bismuth-labeled antibody to gp41 glycoprotein kills ART-treated lymphocytes from HIV patients and HIV-infected monocytes in human blood brain barrier modelMCFARREN A; TSUKROV D; EUGENIN E; LOPEZ L; WILLIAMS D; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; ZOLLA-PAZNER S.; GORNY M.k.; Casadevall Arturo, et alContributions to Conferences
2013213Bi Radioimmunotherapy with an Anti-mCD138 Monoclonal Antibody in a Murine Model of Multiple MyelomaCHEREL M.; GOUARD S.; GASCHET J; SAÏ-MAUREL C; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; BOURGEOIS N.; GESTIN J.-f.; KRAEBER BODÉRÉ F; BARBET J, et alArticles in Journals
2014213Bi-anti-EGFR radioimmunoconjugates and X-ray irradiation trigger different cell death pathways in squamous cell carcinoma cellsPICKHARD Anja; PIONTEK Guido; SEIDL C.; KOPPING Samuel; BLECHERT B.; MISSLBECK Martin; BROCKHOFF Gero; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; ESSLER M.Articles in Journals
2007213bi-Induced Death of Hsc45-M2 Gastric Cancer Cells Is Characterized by G2 Arrest and Up-Regulation of Genes Known to Prevent Apoptosis but Induce Necrosis and Mitotic CatastrpopheSEIDL C.; PORT M.; GILBERTZ K.; MORGENSTERN ALFRED; BRUCHERTSEIFER FRANK; SCHWAIGER M.; ROEPER B.; SENEKOWITSCH-SCHMIDTKE R.; ABEND M.Articles in Journals
2007213Bi-radioimmunotherapy Defeats Early-stage Disseminated Gastric Cancer in Nude MiceBECK R.; SEIDL C.; PFOST B.; MORGENSTERN ALFRED; BRUCHERTSEIFER FRANK; BAUM M.; SCHWAIGER M.; SENEKOWITSCH-SCHMIDTKE R.Articles in Journals
2012Alpha particles and induction of an anti-tumour immune responseGORIN J; GOUARD S.; CHEREL M.; FAIVRE-CHAUVET A; MENAGER J; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; DAVODEAU F; GASCHET JContributions to Conferences
2013Alpha particles induce anti-tumour immunityGORIN J; MÉNAGER Jérémie; GOUARD S.; MAUREL C; CHEREL M.; FAIVRE-CHAUVET A; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; DAVODEAU F; GASCHET JContributions to Conferences
2011An Alpha-Particle Emiting Radiopeptide (213 Bi-DOTA-PESIN) for Therapy of Prostate CancerWILD D.; FRISCHKNECHT M.; ZHANG H.; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; BOISCLAIR J.; PROVENCHER-BOLLIGER A.; REUBI Jean-Claude; MAECKE H. R.Articles in Journals
2013Alpha-particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenationWULBRAND Christian; SEIDL C.; GAERTNER F. C.; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; ESSLER M.; SENEKOWITSCH-SCHMIDTKE R.Articles in Journals
2010[An(H2O)9](CF3SO3)3 (An=U-Cm, Cf): Exploring Their Stability, Structural Chemistry, and Magnetic Behavior by Experiment and TheoryAPOSTOLIDIS Christos; SCHIMMELPFENNIG Bernd; MAGNANI Nicola; LINDQVIST-REIS Patric; WALTER Olaf; SYKORA Richard; MORGENSTERN Alfred; COLINEAU Eric; CACIUFFO Roberto; KLENZE R., et alArticles in Journals
2009Analysis of DNA double-strand breaks in gastric cancer cells after treatment with 213Bi-immunoconjugatesSEIDL C.; FRANK Annette; PFOST B.; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; SENEKOWITSCH-SCHMIDTKE ReingardContributions to Conferences
2011Analysis of Patient Survival in a Phase 1 Trial of Systemic Targeted Alpha Therapy for Metastatic MelanomaALLEN B. J.; SINGLA A; RAJA C.; RIZVI S.; GRAHAM P.; BRUCHERTSEIFER Frank; APOSTOLIDIS Christos; MORGENSTERN AlfredArticles in Journals
2013Anti-PSMA labeled liposomes loaded with Actinium-225 for potential alpha-particle radiotherapy of tumor vasculatureBANDEKAR Amey; ZHU Charles; JINDAL Rohit; BANERJEE Sangeeta Ray; POMPER Martin; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; SOFOU StavroulaContributions to Conferences
2014Anti–Prostate-Specific Membrane Antigen Liposomes Loaded with 225Ac for Potential Targeted Antivascular a-Particle Therapy of CancerBANDEKAR Amey; ZHU Charles; JINDAL Rohit; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; SOFOU StavroulaArticles in Journals
2012Bismuth-213 and Actinium-225 – Generator Performance and Evolving Therapeutic Applications of Two Generator-Derived Alpha-Emitting RadioisotopesMORGENSTERN Alfred; BRUCHERTSEIFER Frank; APOSTOLIDIS ChristosArticles in Journals
2008Bismuth-213 Radioimmunotherapy with C595 Anti¿MUC1 Monoclonal Antibody in an Ovarian Cancer Ascites ModelSONG E.; QU C. F.; RIZVI S.; RAJA C.; BERETOV J.; MORGENSTERN Alfred; APOSTOLIDIS Christos; BRUCHERTSEIFER Frank; PERKINS A. D.Articles in Journals
2012Combined 213Bi-DTPA- F3 and paclitaxel treatment of peritoneal spread of human ovarian carcinoma in a mouse model enhances therapeutic efficacy due to enhanced induction of apoptosis and G2/M phase cell-cycle arrestSEIDL C.; VALLON M.; BLECHERT B.; GILBERTZ K.-P.; AICHLER M; FEUCHTINGER A; GÄRTNER Florian; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; ESSLER M.Contributions to Conferences
2013Comparative analysis of alpha radioimmunotherapy with bismuth-213-labeled anti-CD138 antibody and Melphalan chemotherapy for the treatment of multiple myeloma.GOUARD S.; PALLARDY A; GASCHET J; FAIVRE-CHAUVET A; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; MAUREL C; KRAEBER BODÉRÉ F; BARBET J; DAVODEAU F, et alContributions to Conferences
2014Comparative analysis of multiple myeloma treatment by CD138 antigen targeting with bismuth-213 and Melphalan chemotherapy.GOUARD S.; PALLARDY A; GASCHET J; FAIVRE-CHAUVET A; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; MAUREL C; MATOUS E; KRAEBER BODÉRÉ F; DAVODEAU F, et alArticles in Journals
2012Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer modelGUSTAFSSON Anna; BAECK Tom; ELGQVIST Joergen; JACOBSSON Lars; HULTBORN Ragnar; ALBERTSSON Per; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; JENSEN Holger; LINDEGREN StureArticles in Journals
Showing results 2 to 21 of 86

 

The mission of the JRC is to provide customer-driven scientific and technical support for the conception, development, implementation and monitoring of EU policies. As a service of the European Commission, the JRC functions as a reference centre of science and technology for the Union. Close to the policy-making process, it serves the common interest of the Member States, while being independent of special interests, whether private or national.
Powered by DSpace
Top